Comstock Announces Strategic Partnership with EFT Comstock has recently revealed a significant strategic partnership between its subsidiary, Comstock IP Holdings …
Read More »Harrow obtains Santen’s ophthalmic portfolio in 6-8 words.
According to Harrow, the transaction Includes U.S. and Canadian commercial rights to six therapeutics, including two non-prescription brands. Harrow today announced the signing of agreements with affiliates of Santen Pharmaceutical Co., Ltd. to acquire certain U.S. and Canadian commercial rights for six branded products from Santen. According to the company, U.S. products include: FLAREX (fluorometholone acetate ophthalmic suspension) 0.1%, a …
Read More »